Drugs / KITE-753
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07674823 | Dec 2026 → Apr 2029 expected | B-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04989803 | Oct 2021 → Feb 2030 expected | B-cell non-Hodgkin lymphoma | Kite, A Gilead Company | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07479797 | May 2026 → May 2031 expected | large B-cell lymphoma | Kite, A Gilead Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KITE-753 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07479797 ↗ |
| Modality | Cell therapy | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT04989803 ↗ |
| Route | Intravenous | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT04989803 ↗ |